Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart failure drug trial pulled before it even started

NCT ID NCT05953831

Disease control Sponsor: Cardior Pharmaceuticals GmbH Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jul 08, 2026 · Updated 3 times

Summary

This was a planned Phase 2 study testing a drug called CDR132L in about 130 people with heart failure and a preserved or mildly reduced ejection fraction. The drug aimed to reverse harmful changes in the heart muscle. However, the trial was withdrawn before any participants were enrolled, so no results are available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CDR132L (a synthetic molecule that blocks a specific microRNA linked to heart damage)
What this could lead to
If successful, this could point toward a treatment that reverses heart muscle thickening and improves heart function in certain types of heart failure.
What could go wrong
This trial was withdrawn before enrolling any participants, so no data exists yet. Even if tested, early-phase studies often fail to show benefit in larger populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Expected to start

Apr 2024

An estimate. Start dates often move.

Expected to finish

Sep 2025

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Main Inclusion Criteria: 1. Provision of signed informed consent prior to any study-specific procedures. 2. Male or female of non-childbearing potential patients age ≥40 and \<85 years. 3. Documented diagnosis of symptomatic heart failure (NYHA class II-IV) at enrollment, and a medical history of typical symptoms/signs of heart failure ≥6 weeks before enrollment with at least intermittent need for diuretic treatment. 4. Ejection fraction ≥45% (determined by echocardiography at site laboratory) 5. Increased intraventricular wall thickness (≥11 mm for female and ≥12 mm for male patients by echocardiography at site laboratory) 6. NT-proBNP \> 300 pg/ml (sinus rhythm); \>900 pg/ml (atrial fibrillation at time of screening/inclusion or documented with the last 6 months) 7. BMI between 22 kg/m² and 45 kg/m². Main Exclusion Criteria: 1. Hemoglobin A1C (A1C) ≥10.5% 2. eGFR \<35 mL/min/1.73m² 3. Systolic blood pressure (BP) \<90 mmHg on 2 consecutive measurements at 5-minute intervals, at Screening. 4. Systolic BP≥180 mmHg on 2 consecutive measurements at 5-minute intervals, at Screening. 5. Planned coronary revascularization, ablation of atrial flutter/fibrillation and valve repair/replacement. 6. Stroke or transient ischemic attack (TIA) within 12 weeks prior to enrolment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure with preserved ejection fraction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cardiomegaly diastolic heart failure heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure with preserved ejection fraction

More trials for these conditions

Other studies related to the condition(s) this trial covers.